EURAMOS-1-PR

NCT00134030 📎

Regimen

Experimental
MAPIE post-op (MAP + ifosfamide + etoposide intensification)
Control
MAP continued post-op

Population

Resectable high-grade osteosarcoma, age <=40, POOR histologic response (>=10% viable tumor) to neoadjuvant MAP

Key finding

Adding ifosfamide/etoposide to MAP for poor responders did NOT improve EFS/OS. Significant grade 3-4 toxicity and secondary AML excess. MAP backbone confirmed as unbeaten for 40+ years.

Source: PMID 27569442

Timeline

    Guideline citations

    • NCCN BONE (p.33)